Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7606893 | 0.86 | KDM4E (0.45) | KDM4EALDH1A1HTTTLR8SMPD1 | |
| SCHEMBL7607033 | 0.84 | TLR8 (0.44) | TLR8SMPD1MAPTPTGS2GRM2 | |
| SCHEMBL6732709 | 0.74 | PTGS2 (0.42) | KDM4EALDH1A1POLBHTTMAPT | |
| SCHEMBL7611396 | 0.73 | CNR2 (0.44) | ALDH1A1MAPTCA9 | |
| SCHEMBL6935385 | 0.72 | KDM4E (0.47) | KDM4EALDH1A1POLBHTTENPP2 | |
| SCHEMBL7606912 | 0.71 | ALDH1A1 (0.50) | KDM4EALDH1A1POLBHTTMAPT | |
| SCHEMBL12297640 | 0.68 | ALDH1A1 (0.48) | KDM4EALDH1A1POLBHTTTLR8 | |
| SCHEMBL4623128 | 0.67 | KDM4E (0.42) | KDM4EALDH1A1POLBHTTENPP2 | |
| Dodecane SCHEMBL28192320 | 0.67 | SMN1; SMN2 (0.56) | KDM4EALDH1A1GAATHRB | |
| SCHEMBL6730881 | 0.66 | NR1H2 (0.37) | KDM4EALDH1A1POLBHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020031536-A1 | Cosmetic compositions based on 4,5-pyrazolinediones, novel 4,5-pyrazolinediones, process for their preparation and uses thereof | L'OREAL SA | 2002-03-14 | — | — | US | disclosed |
| US-6322775-B1 | FOR COLORING THE SKIN AND/OR THE HAIR; SIDE EFFECTS REDUCTION; STABILITY | L'OREAL S.A. (FR) | 2001-11-27 | — | — | US | disclosed |
| EP-0888306-B1 | COSMETIC COMPOSITIONS CONTAINING PYRAZOLIN-4,5-DIONES, NOVEL PYRAZOLIN-4,5-DIONES, PREPARATION METHODS THEREFOR AND USES THEREOF | OREAL (FR) | 2001-07-25 | — | — | EP | disclosed |
| EP-0888306-A1 | COSMETIC COMPOSITIONS CONTAINING PYRAZOLIN-4,5-DIONES, NOVEL PYRAZOLIN-4,5-DIONES, PREPARATION METHODS THEREFOR AND USES THEREOF | L'OREAL (FR) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997035842-A1 | COSMETIC COMPOSITIONS CONTAINING PYRAZOLIN-4,5-DIONES, NOVEL PYRAZOLIN-4,5-DIONES, PREPARATION METHODS THEREFOR AND USES THEREOF | L'OREAL (FR) | 1997-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020031536-A1 | Cosmetic compositions based on 4,5-pyrazolinediones, novel 4,5-pyrazolinediones, process for their preparation and uses thereof | PPARD, PLIN5, PDK4 | KDM4E 626/4885ALDH1A1 263/4885POLB 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.